Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Bolt Biotherapeutics, Inc.

Clinical trials sponsored by Bolt Biotherapeutics, Inc., explained in plain language.

Bolt Biotherapeutics, Inc. BOLT NASDAQ

Develops immuno-oncology therapies using antibody-drug conjugates and immune-stimulating payloads.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Terminated 3

New drug BDC-4182 targets stomach cancer by waking up the immune system

Disease control Recruiting now

This early-phase trial is testing a new drug called BDC-4182 in people with advanced gastric or gastroesophageal cancer that has spread or cannot be removed. The drug is designed to attach to a protein on cancer cells and stimulate the immune system to attack them. The study will…

Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC